BACKGROUND:Depressed patients with comorbid personality pathology may fare worse in treatment for depression than those without this additional pathology, and comorbid personality pathology may be associated with superior response in one form of treatment relative to another, though recent findings have been mixed. We aimed to evaluate the effect of personality pathology on time to remission of patients randomly assigned to 1 of 2 treatment strategies for depression and to determine whether personality pathology moderated the effect of treatment assignment on outcome. METHOD: Individuals undergoing an episode of unipolar major depression (n = 275) receivedinterpersonal psychotherapy (Klerman, Weissman, Rounsaville, & Chevron, 1984) or selective serotonin reuptake inhibitor (SSRI) pharmacotherapy for depression. Depressive symptoms were measured with the HRSD-17. Remission was a mean HRSD-17 score of 7 or below over a period of 3 weeks. Personality disorders were measured according to SCID-II diagnoses, and personality pathology was measured dimensionally by summing the positive probes on the SCID-II. RESULTS: The presence of at least 1 personality disorder was not a significant predictor of time to remission, but a higher level of dimensionally measured personality pathology and the presence of borderline personality disorder were associated with a longer time to remission. Personality pathology did not moderate the effect of treatment assignment on time to remission. CONCLUSIONS: The findings suggest that depressed individuals with comorbid personality pathology generally fare worse in treatment for depression, although in this report, the effect of personality pathology did not differ by the type of treatment received. (PsycINFO Database Record (c) 2012 APA, all rights reserved).
RCT Entities:
BACKGROUND:Depressedpatients with comorbid personality pathology may fare worse in treatment for depression than those without this additional pathology, and comorbid personality pathology may be associated with superior response in one form of treatment relative to another, though recent findings have been mixed. We aimed to evaluate the effect of personality pathology on time to remission of patients randomly assigned to 1 of 2 treatment strategies for depression and to determine whether personality pathology moderated the effect of treatment assignment on outcome. METHOD: Individuals undergoing an episode of unipolar major depression (n = 275) received interpersonal psychotherapy (Klerman, Weissman, Rounsaville, & Chevron, 1984) or selective serotonin reuptake inhibitor (SSRI) pharmacotherapy for depression. Depressive symptoms were measured with the HRSD-17. Remission was a mean HRSD-17 score of 7 or below over a period of 3 weeks. Personality disorders were measured according to SCID-II diagnoses, and personality pathology was measured dimensionally by summing the positive probes on the SCID-II. RESULTS: The presence of at least 1 personality disorder was not a significant predictor of time to remission, but a higher level of dimensionally measured personality pathology and the presence of borderline personality disorder were associated with a longer time to remission. Personality pathology did not moderate the effect of treatment assignment on time to remission. CONCLUSIONS: The findings suggest that depressed individuals with comorbid personality pathology generally fare worse in treatment for depression, although in this report, the effect of personality pathology did not differ by the type of treatment received. (PsycINFO Database Record (c) 2012 APA, all rights reserved).
Authors: Janet D Carter; Suzanne E Luty; Janice M McKenzie; Roger T Mulder; Christopher M Frampton; Peter R Joyce Journal: J Affect Disord Date: 2010-08-01 Impact factor: 4.839
Authors: E Frank; G B Cassano; P Rucci; W K Thompson; H C Kraemer; A Fagiolini; L Maggi; D J Kupfer; M K Shear; P R Houck; S Calugi; V J Grochocinski; P Scocco; J Buttenfield; R N Forgione Journal: Psychol Med Date: 2010-04-12 Impact factor: 7.723
Authors: Andrew E Skodol; Donna S Bender; Leslie C Morey; Lee Anna Clark; John M Oldham; Renato D Alarcon; Robert F Krueger; Roel Verheul; Carl C Bell; Larry J Siever Journal: J Pers Disord Date: 2011-04
Authors: A E Skodol; R L Stout; T H McGlashan; C M Grilo; J G Gunderson; M T Shea; L C Morey; M C Zanarini; I R Dyck; J M Oldham Journal: Depress Anxiety Date: 1999 Impact factor: 6.505
Authors: E Frank; V J Grochocinski; C A Spanier; D J Buysse; C R Cherry; P R Houck; D M Stapf; D J Kupfer Journal: J Clin Psychiatry Date: 2000-01 Impact factor: 4.384
Authors: Rachel E Maddux; Lawrence P Riso; Daniel N Klein; John C Markowitz; Barbara O Rothbaum; Bruce A Arnow; Rachel Manber; Janice A Blalock; Gabor I Keitner; Michael E Thase Journal: J Affect Disord Date: 2009-02-12 Impact factor: 4.839
Authors: Joanna M Berg; Jamie C Kennedy; Boadie W Dunlop; Cynthia L Ramirez; Lindsay M Stewart; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead Journal: Pers Med Psychiatry Date: 2017-01-05
Authors: Jay C Fournier; Henry W Chase; Tsafrir Greenberg; Amit Etkin; Jorge R Almeida; Richelle Stiffler; Thilo Deckersbach; Sarah Weyandt; Crystal Cooper; Marisa Toups; Tom Carmody; Benji Kurian; Scott Peltier; Phillip Adams; Melvin G McInnis; Maria A Oquendo; Patrick J McGrath; Maurizio Fava; Myrna Weissman; Ramin Parsey; Madhukar H Trivedi; Mary L Phillips Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2016-12-06
Authors: Bianca E Kavanagh; Lana J Williams; Michael Berk; Alyna Turner; Henry J Jackson; Mohammadreza Mohebbi; Buranee Kanchanatawan; Melanie M Ashton; Chee H Ng; Michael Maes; Lesley Berk; Gin S Malhi; Nathan Dowling; Ajeet B Singh; Olivia M Dean Journal: Braz J Psychiatry Date: 2020 Jan-Feb Impact factor: 2.697